Remove GlobalData Healthcare
article thumbnail

Leading innovators in coronavirus vaccine components

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

article thumbnail

GSK’s Arexvy Leads Over Pfizer’s Abrysvo in Year One of RSV Vaccine Market Battle

XTalks

In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo. Going up against vaccine stalwart Pfizer wasn’t an easy feat but GSK succeeded in the challenge by taking an early lead in the RSV vaccine battle. billion or £1.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ESG Top Trends: Healthcare ESG Impact

Pharmaceutical Technology

All aspects of environmental, social, and governance (ESG) are important, and in the healthcare industry, companies must excel across all three. Listed below are the impact of ESG on healthcare, as identified by GlobalData. The post ESG Top Trends: Healthcare ESG Impact appeared first on Pharmaceutical Technology.

Medicine 162
article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing-December

Pharmaceutical Technology

The data, which is collated from the GlobalData Pharma Intelligence Center’s Deals Database and PharmSource reports on these outsourcing relationships, provides a glimpse of not only the different players involved in the pharma supply value chain, but also the nature of the contracts that link them.

article thumbnail

BI-685509 by Boehringer Ingelheim International for Systemic Sclerosis (Scleroderma): Likelihood of Approval

Pharmaceutical Technology

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

article thumbnail

ESG Top Trends: Macroeconomic trends

Pharmaceutical Technology

As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. Climate change and ESG. Drug pricing and gouging.